image1

WHY Et-traps? pharmaceutical company

Endothelin-1–Induced Endoplasmic Reticulum Stress in Disease : Arjun Jain

Journal of Pharmacology and Experimental Therapeutics, 2013


Although the use of ET receptor antagonists has been useful in ameliorating disease pathology, there are certain draw- backs to consider. The use of ET antagonists has previously been associated with side effects, such as an increase in heart rate, facial flush, and/or facial edema (Fleisch et al., 2000). In addition, certain ET antagonists may interfere with anticoagulants, such as warfarin, and therefore pose a risk of thrombosis (Weber et al., 1999). These studies indicate the importance of only regulated antagonism of the ET receptor system as a therapeutic tool. 


An alternative strategy for prevention of ET-1–induced pathology would be to target the actual elevated levels of ET-1 in pathologic conditions.


At ET-traps Limited, we have developed an Fc-based fusion protein that has a very high binding affinity; in the pico molar range, which is higher than  ERAs that are already in clinical use.


Creating a Soluble Binder to Endothelin-1 Based on the Natural Ligand Binding Domains of the Endothelin-1 (G-Protein-Coupled) Receptor: Arjun Jain et al., International Journal of Peptide Research and Therapeutics, 2017

Our PoC work (both in vitro and in vivo) has shown that the ET-traps are non- toxic or cytotoxic at the working concentration, which gives an efficacious effect.


In vitro

Endothelin-1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes; Arjun Jain et al.,  Journal of Diabetes & Metabolic Disorders, 2018

     

  • ET- traps have efficacious effect on markers of pathology after both high endothelin-1 and high glucose treatment,
  • High glucose induced expression of the markers of pathology tested is dependent on endothelin-1 

In vivo 

 In vivo studies demonstrate that endothelin-1 traps are a potential therapy for type I diabetes; Arjun Jain et al.,  Journal of Diabetes & Metabolic Disorders, 2019  [Accepted, under Publication]

     

  • Although ET-traps do not affect glucose levels, ET-traps have an efficacious, therapeutic effect on different factors of diabetic pathology, including diabetic cardiomyopathy, CKD, and other markers in the heart and kidney
     
  • All markers of pathology return to basal, non-diabetic levels after treatment with ET-traps 


                                                                  AFFORDABLE, SIMPLE AND SAFE


  • NON- TOXIC
  • SIGNIFICANTLY DECREASE ELEVATED LEVELS OF ET-1 TO THE NORMAL PHYSIOLOGICAL LEVEL.
  • HIGH BINDING AFFINITY
  • IT IS A Fc-FUSION PROTEIN (FFP) AND SO HAS A LONGER SERUM HALF LIFE. 
  • NON-IMMUNOGENIC : The FFPs can be modulated more easily so that the therapy does not elicit any negative immune reaction.
  • COST EFFECTIVE
  • ABLE TO HELP WITH BROAD RANGE OF DISEASES (elevated endothelin-1 levels)


 

Learn More

To know more about Endothelin-1 being implicated in a host of different diseases and its effects, current treatment options, click the link below.

Find out more

Key Publications

image2
image3
image4
image5
image6
image7

awards

Winner, Biotech startup weekend 2015, Cambridge, UK

image8

Find out more

WINNER AT Biotech Startup Astra Zeneca Judge Business School, University of cambridge